Prostate cancer: A guide for men who've just been diagnosed

• Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. Jama. 2005;293(17):2095–101.
• Alkhorayef M, Mahmoud MZ, Alzimami KS, Sulieman A, Fagiri MA. High-Intensity Focused Ultrasound (HIFU) in Localized Prostate Cancer Treatment. Pol J Radiol. 2015;80:131–41.
• Autran-Gomez AM, Scarpa RM, Chin J. High-Intensity Focused Ultrasound and Cryotherapy as Salvage Treatment in Local Radio-Recurrent Prostate Cancer. Urol Int. 2012;89(4):373–9.
• Berkey FJ. Managing the adverse effects of radiation therapy. Am Fam Physician. 2010 Aug 15;82(4):381–8, 394.
• Berney DM. The case for modifying the Gleason grading system. BJU Int. 2007;100(4):725–6.
• Bhatnagar V, Stewart ST, Huynh V, Jorgensen G, Kaplan RM. Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment. Prostate Cancer Prostatic Dis. 2006;9(2):136–46.
• Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011 Jul 1;117(13):2883–91.
• Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, et al. Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation. J Clin Oncol. 2014 Jun 10;32(17):1840–50.
• British Uro-oncology Group (BUG), British Association of Urological Surgeons (BAUS). Multi-disciplinary Team (MDT) Guidance for Managing Prostate Cancer. 2013.
• Cancer Research UK. Lifetime risk estimates calculated by the Statistical Information Team at Cancer Research UK. Based on data provided by the Office of National Statistics, ISD Scotland, the Welsh Cancer Intelligence and Surveillance Unit and the Northern Ireland Cancer Registry, on request, December 2013 to July 2014. 2016.
• Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, et al. Cancer Control and Functional Outcomes of Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Systematic Review of the Literature. Eur Urol. 2012 May;61(5):961–71.
• Chen AB, D’Amico AV, Neville BA, Earle CC. Patient and Treatment Factors Associated With Complications After Prostate Brachytherapy. J Clin Oncol. 2006 Jan 3;24(33):5298–304.
• Collin SM, Metcalfe C, Donovan J, Lane JA, Davis M, Neal D, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int. 2008 Jun 6;0(0):080606123516618 – ???
• Crawford ED. Understanding the Epidemiology, Natural History, and Key Pathways Involved in Prostate Cancer. Urology. 2009 May;73(5):S4–10.
• de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147–54.
• Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52.
• Gardner JR, Livingston PM, Fraser SF. Effects of Exercise on Treatment-Related Adverse Effects for Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Systematic Review. J Clin Oncol. 2014 Feb 1;32(4):335–46.
• Gomez-Veiga F, Mariño A, Alvarez L, Rodriguez I, Fernandez C, Pertega S, et al. Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy. BJU Int. 2012;109(s1):17–21.
• Gruca D, Bacher P, Tunn U. Safety and tolerability of intermittent androgen deprivation therapy: A literature review: IAD therapy in prostate cancer. Int J Urol. 2012 Jul;19(7):614–25.
• Hechtman LM. Clinical Naturopathic Medicine [Internet]. Harcourt Publishers Group (Australia); 2014 [cited 2015 Jul 21]. 1610 p. Available from: http://www.bookdepository.com/Clinical-Naturopathic-Medicine-Leah-Hechtman/9780729541923
• Henson CC, Burden S, Davidson SE, Lal S. Nutritional interventions for reducing gastrointestinal toxicity in adults undergoing radical pelvic radiotherapy. The Cochrane Collaboration, editor. Cochrane Database Syst Rev [Internet]. 2013 [cited 2014 Nov 18];(11). Available from: http://doi.wiley.com/10.1002/14651858.CD009896.pub2
• Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003;61(2):32–8.
• Husson O, Mols F, Poll-Franse LV van de. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol. 2010 Sep 24;mdq413.
• James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the ‘Docetaxel Era’: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015 Jun;67(6):1028–38.
• Johansson J-E, Andrén O, Andersson S-O, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA J Am Med Assoc. 2004 Jun 9;291(22):2713–9.
• Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003;91(9):789–94.
• Jones AL, Chinegwundoh F. Update on prostate cancer in black men within the UK. Ecancermedicalscience. 2014;8:455.
• Keogh JWL, MacLeod RD. Body Composition, Physical Fitness, Functional Performance, Quality of Life, and Fatigue Benefits of Exercise for Prostate Cancer Patients: A Systematic Review. J Pain Symptom Manage. 2012 Jan;43(1):96–110.
• Kiciński M, Vangronsveld J, Nawrot TS. An Epidemiological Reappraisal of the Familial Aggregation of Prostate Cancer: A Meta-Analysis. Little J, editor. PLoS ONE. 2011 Oct 31;6(10):e27130.
• Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int. 2010 Jan;105(2):191–201.
• Kumar RJ. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol. 2005;7(Suppl 5):S37.
• Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92(S6):1684–8.
• Langston B, Armes J, Levy A, Tidey E, Ream E. The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2013 Jun;21(6):1761–71.
• Larkin D, Lopez V, Aromataris E. Managing cancer-related fatigue in men with prostate cancer: A systematic review of non-pharmacological interventions: Managing prostate cancer fatigue. Int J Nurs Pract. 2014 Oct;20(5):549–60.
• Levy D, Avallone A, Jones JS. Current state of urological cryosurgery: prostate and kidney. BJU Int. 2010;105(5):590–600.
• Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010. BMC Med [Internet]. 2015 Dec [cited 2015 Nov 5];13(1). Available from: http://www.biomedcentral.com/1741-7015/13/171
• Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol. 2007 Apr 20;25(12):1596–605.
• Lukka H, Waldron T, Chin J, Mayhew L, Warde P, Winquist E, et al. High-intensity Focused Ultrasound for Prostate Cancer: a Systematic Review. Clin Oncol. 2011 Mar;23(2):117–27.
• McCaughan E, McSorley O, Prue G, Parahoo K, Bunting B, Sullivan JO, et al. Quality of life in men receiving radiotherapy and neo-adjuvant androgen deprivation for prostate cancer: results from a prospective longitudinal study: Prostate cancer and QoL: a longitudinal study. J Adv Nurs. 2013 Jan;69(1):53–65.
• Mishra SI, Scherer RW, Geigle PM, Berlanstein DR, Topaloglu O, Gotay CC, et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev. 2012;8:CD007566.
• Moch H, Cubilla A, Humphrey P, Reuter V, Ulbright T. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and BladderTumours [Internet]. 2016. Available from: http://www.europeanurology.com/article/S0302-2838%2816%2900205-0/abstract/the-2016-who-classification-of-tumours-of-the-urinary-system-and-male-genital-organs-part-b-prostate-and-bladder-tumours
• Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, et al. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):204–12.
• Morton GC, Loblaw DA, Sankreacha R, Deabreu A, Zhang L, Mamedov A, et al. Single-Fraction High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiotherapy for Men With Intermediate-Risk Prostate Cancer: Analysis of Short- and Medium-Term Toxicity and Quality of Life. Int J Radiat Oncol. 2010 Jul;77(3):811–7.
• Mottet N, Bellmunt J, Briers E, Bolla M, Cornford P, De Santis M, et al. EAU Guidelines on Prostate Cancer 2016 [Internet]. European Association of Urology; 2016. Available from: http://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2016.pdf
• Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int. 2006 Jul;98(1):20–7.
• Murphy R, Wassersug R, Dechman G. The role of exercise in managing the adverse effects of androgen deprivation therapy in men with prostate cancer. Phys Ther Rev. 2011 Aug 1;16(4):269–77.
• National Institute for Clinical Excellence. High-intensity focused ultrasound for prostate cancer. Interventional procedure guidance 118. 2005.
• National Institute for Health and Care Excellence (NICE). Osteoporosis - prevention of fragility fractures - Clinical Knowledge Summary [Internet]. 2016. Available from: http://cks.nice.org.uk/osteoporosis-prevention-of-fragility-fractures#!scenario:1
• National Institute for Health and Care Excellence. Prostate Cancer: diagnosis and treatment. Full guideline 175. 2014.
• National Institute for Health and Clinical Excellence (Great Britain). Low dose rate brachytherapy for localised prostate cancer. London: National Institute for Health and Clinical Excellence; 2005.
• National Institute for Health and Clinical Excellence. Cryotherapy as a primary treatment for prostate cancer. Interventional procedure guidance 145. 2005.
• National Institute for Health and Clinical Excellence. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer. NICE technology appraisal guidance 101. 2006.
• National Institute for Health and Clinical Excellence. High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer. 2006;
• Neto AS, Tobias-Machado M, Esteves MAP, Senra MD, Wroclawski ML, Fonseca FLA, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2012;15(1):36–44.
• NHS England. Docetaxel in combination with androgen deprivation therapy for the treatment of hormone naïve metastatic prostate cancer. 2016.
• O’Connor KM, Fitzpatrick JM. Side-effects of treatments for locally advanced prostate cancer. BJU Int. 2006 Jan;97(1):22–8.
• O’Donnell H, Parker C. What is low-risk prostate cancer and what is its natural history? World J Urol. 2008 Oct 1;26(5):415–22.
• Palermo G, Pinto F, Totaro A, Miglioranza E, Calarco A, Sacco E, et al. High-intensity focused ultrasound in prostate cancer: today’s outcomes and tomorrow’s perspectives. Scand J Urol. 2013 Jun;47(3):179–87.
• Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013;369(3):213–23.
• Peinemann F, Grouven U, Bartel C, Sauerland S, Borchers H, Pinkawa M, et al. Permanent Interstitial Low-Dose-Rate Brachytherapy for Patients with Localised Prostate Cancer: A Systematic Review of Randomised and Nonrandomised Controlled Clinical Trials. Eur Urol. 2011 Nov;60(5):881–93.
• Peinemann F, Grouven U, Hemkens LG, Bartel C, Borchers H, Pinkawa M, et al. Low-dose rate brachytherapy for men with localized prostate cancer. In: The Cochrane Collaboration, Peinemann F, editors. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2011 [cited 2013 Dec 10]. Available from: http://doi.wiley.com/10.1002/14651858.CD008871.pub2
• Pettersson A, Johansson B, Persson C, Berglund A, Turesson I. Effects of a dietary intervention on acute gastrointestinal side effects and other aspects of health-related quality of life: A randomized controlled trial in prostate cancer patients undergoing radiotherapy. Radiother Oncol. 2012 Jun;103(3):333–40.
• Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, et al. Early Salvage Radiotherapy Following Radical Prostatectomy. Eur Urol. 2014 Jun;65(6):1034–43.
• Pisansky TM, Gold DG, Furutani KM, Macdonald OK, McLaren RH, Mynderse LA, et al. High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer. In: Mayo Clinic Proceedings [Internet]. Elsevier; 2008 [cited 2014 Apr 24]. p. 1364–72. Available from: http://www.sciencedirect.com/science/article/pii/S0025619611607854
• Popiolek M, Rider JR, Andrén O, Andersson S-O, Holmberg L, Adami H-O, et al. Natural History of Early, Localized Prostate Cancer: A Final Report from Three Decades of Follow-up. Eur Urol. 2013;63(3):428–35.
• Prada PJ, González H, Fernández J, Jiménez I, Iglesias A, Romo I. Biochemical outcome after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience: HIGH-DOSE-RATE BRACHYTHERAPY +EBRT FOR PROSTATE CANCER. BJU Int. 2012 Jun;109(12):1787–93.
• Price CP, Allard J, Davies G, Dawnay A, Duffy MJ, France M, et al. Pre-and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem. 2001;38(3):188–216.
• Price JG, Stone NN, Stock RG. Predictive Factors and Management of Rectal Bleeding Side Effects Following Prostate Cancer Brachytherapy. Int J Radiat Oncol. 2013 Aug;86(5):842–7.
• Public Health England. Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing [Internet]. GOV.UK; 2016. Available from: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks/prostate-cancer-risk-management-programme-pcrmp-benefits-and-risks-of-psa-testing
• Public Health England. Prostate cancer risk management programme (PCRMP): PSA test benefits and risks [Internet]. 2016 [cited 2016 May 4]. Available from: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks
• Punnen S, Cooperberg MR, D’Amico AV, Karakiewicz PI, Moul JW, Scher HI, et al. Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature. Eur Urol. 2013 Dec;64(6):905–15.
• Rosoff JS, Savage SJ, Prasad SM. Salvage radical prostatectomy as management of locally recurrent prostate cancer: outcomes and complications. World J Urol. 2013 Dec;31(6):1347–52.
• Saylor PJ, Smith MR. Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2013 Jan;189(1):S34–44.
• Serpa Neto A, Tobias-Machado M, Kaliks R, Wroclawski ML, Pompeo ACL, Del Giglio A. Ten Years of Docetaxel-Based Therapies in Prostate Adenocarcinoma: A Systematic Review and Meta-Analysis of 2244 Patients in 12 Randomized Clinical Trials. Clin Genitourin Cancer. 2011 Dec;9(2):115–23.
• Shelley M, Wilt T, Coles B, Mason M. Cryotherapy for localised prostate cancer (Review). The Cochrane Collaboration, editor. Cochrane Database Syst Rev. 2007;(3).
• Singer EA, Srinivasan R. Intravenous therapies for castration-resistant prostate cancer: Toxicities and adverse events. Urol Oncol Semin Orig Investig. 2012 Jul;30(4):S15–9.
• Sountoulides P, Rountos T. Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer: Prevention and Management. ISRN Urol [Internet]. 2013 Jul 25 [cited 2015 Nov 3];2013. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747499/
• Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 2014 Mar 24;
• Storey DJ, McLaren DB, Atkinson MA, Butcher I, Frew LC, Smyth JF, et al. Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Ann Oncol. 2011 Oct 17;23(6):1542–9.
• Sung HH, Jeong BC, Seo SI, Jeon SS, Choi H-Y, Lee HM. Seven years of experience with high-intensity focused ultrasound for prostate cancer: Advantages and limitations. The Prostate. 2012 Sep 15;72(13):1399–406.
• Tanaka N, Asakawa I, Anai S, Hirayama A, Hasegawa M, Konishi N, et al. Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy. Radiat Oncol. 2013;8(1):25.
• Thompson et al. Prevalence of PCA among men with low PSA.pdf. 2004;
• Tillisch K. Complementary and alternative medicine for functional gastrointestinal disorders. Gut. 2006 May 1;55(5):593–6.
• Trottier G, Boström PJ, Lawrentschuk N, Fleshner NE. Nutraceuticals and prostate cancer prevention: a current review. Nat Rev Urol. 2009 Dec 8;7(1):21–30.
• Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, et al. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Apr;69(4):563–73.
• Van Patten CL, de Boer JG, Tomlinson Guns ES. Diet and Dietary Supplement Intervention Trials for the Prevention of Prostate Cancer Recurrence: A Review of the Randomized Controlled Trial Evidence. J Urol. 2008 Dec;180(6):2314–22.
• Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. The Lancet. 2011 Dec;378(9809):2104–11.
• Wedlake LJ, Shaw C, Whelan K, Andreyev HJN. Systematic review: the efficacy of nutritional interventions to counteract acute gastrointestinal toxicity during therapeutic pelvic radiotherapy. Aliment Pharmacol Ther. 2013 Jun;37(11):1046–56.
• White ID, Wilson J, Aslet P, Baxter AB, Birtle A, Challacombe B, et al. Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer. Int J Clin Pract. 2015 Jan;69(1):106–23.
• Widmark A, Klepp O, Solberg A, Damber J-E, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009 Jan 24;373(9660):301–8.
• Zaorsky NG, Doyle LA, Yamoah K, Andrel JA, Trabulsi EJ, Hurwitz MD, et al. High dose rate brachytherapy boost for prostate cancer: A systematic review. Cancer Treat Rev. 2014 Apr;40(3):414–25.
• Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol. 2008;70(4):1124–9.

This booklet is for men who’ve recently been diagnosed with
prostate cancer. We explain what prostate cancer is, the tests you may have to diagnose it, and the treatment options available.